PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia
The purpose of this study is to estimate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer receiving chemotherapy.
Breast Cancer
DRUG: PEG-rhG-CSF
the occurrence rate of the adverse events that are related to treatment during four consecutive cycles chemotherapy, up to 30 days after the patient study completion|the severity of the adverse events that are related to treatment during four consecutive cycles chemotherapy, up to 30 days after the patient study completion
the occurrence rate of III/ IV neutropenia during the whole chemotherapy process, through the study completion,an average of 5 months
The purpose of this study is to estimate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer receiving chemotherapy.